Open Access Government produces compelling and informative news, publications, eBooks, and academic research articles for the public and private sector looking at health, diseases & conditions, workplace, research & innovation, digital transformation, government policy, environment, agriculture, energy, transport and more.
Home 2023
Archives
The global regulatory landscape for psychedelic drugs
Jessica Riggleman, Owner of Raeco, LLC, examines the global regulatory landscape for psychedelic drugs, with a particular focus on Schedule I classification.
Beyond amyloid: What’s next for Alzheimers disease therapeutics?
Bradlee Heckmann, PhD, from USF Health Neuroscience Institute, Byrd Alzheimer’s Center & Asha Therapeutics, in this discussion goes beyond amyloid, asking what’s next for Alzheimer’s Disease therapeutics.
Brain health conditions: Excellence in psychedelic treatments
Psychedelic treatments open up an unparalleled window of opportunity, but we need to get ready for their roll-out.
The fentanyl crisis: Death at the end of the rainbow
Chelsea Unkel, Ryan Hogans, & Pamela Lein from the University of California, Davis, analyse the fentanyl crisis responsible for increases in drug overdose across the US.
Evaluating a novel treatment for opioid use disorder based on dual-brain psychology and photobiomodulation
Dr. Fredric Schiffer, founder and CEO of MindLight, LLC, looks at treatments for opioid use disorder based on Dual-Brain Psychology and photobiomodulation. Dr. Schiffer is also a part-time assistant professor in psychiatry at Harvard Medical School.
Alzheimer’s drug slows memory decline in phase 3 trial
Henry Scowcroft from Alzheimer’s Research UK, argues that an Alzheimer’s drug, lecanemab, can slow memory decline in a phase 3 trial.
Tuberculosis drug regimens and their efficacies
Andrew Nunn, Professor of Epidemiology in the Medical Research Council Clinical Trials Unit at UCL, analyses tuberculosis drug development.
